The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: MT-ATP8 CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: NC_012920.1(MT-ATP8):m.8553C>T

CA414796661

618720 (ClinVar)

Gene: MT-ATP8
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: bb4e86f8-3f2d-49f3-b92e-4c2fbde40d4e
Approved on: 2023-06-26
Published on: 2025-06-03

HGVS expressions

NC_012920.1:m.8553C>T
J01415.2:m.8553C>T
ENST00000361851.1:c.188C>T
ENST00000361899.2:c.27C>T
More

Uncertain Significance

Met criteria codes 1
PP3
Not Met criteria codes 5
PM2 PM6 PS3 PS4 PS2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.8553C>T (p.F9F in MT-ATP6; p.S63L in MT-ATP8) was reviewed by the Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel on June 26, 2023. There are no individuals or families with primary mitochondrial disease with this variant reported in the medical literature to our knowledge. This variant is present in population databases and is seen in individuals from several different haplogroups (MITOMAP: 0.023%, 14/61,883; gnomAD v3.1.2: 0.041%, 23/56,428 homoplasmic occurrences; Helix: 0.009%, 18/195,893 homoplasmic occurrences). The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.7 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). There are no cybrids, single fiber studies, or other functional assays reported for this variant. In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on June 26, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PP3.
Met criteria codes
PP3
The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.7 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3).
Not Met criteria codes
PM2
This variant is present in population databases and is seen in individuals from several different haplogroups (MITOMAP: 0.023%, 14/61,883; gnomAD v3.1.2: 0.041%, 23/56,428 homoplasmic occurrences; Helix: 0.009%, 18/195,893 homoplasmic occurrences).
PM6
There are no individuals or families with primary mitochondrial disease with this variant reported in the medical literature to our knowledge.
PS3
There are no cybrids, single fiber studies, or other functional assays reported for this variant.
PS4
There are no individuals or families with primary mitochondrial disease with this variant reported in the medical literature to our knowledge.
PS2
There are no individuals or families with primary mitochondrial disease with this variant reported in the medical literature to our knowledge.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.